Flavored vapes and the controversy dividing the FDA
Three health policy researchers break down the science behind flavored vapes—and what the FDA leadership shake-up means for public health—in this piece written for The Conversation.
Three health policy researchers break down the science behind flavored vapes—and what the FDA leadership shake-up means for public health—in this piece written for The Conversation.
Quitting smoking even at the advanced age of 75 can meaningfully extend a person's life expectancy, according to new research from the University of Michigan School of Public Health.
The decrease in cigarette smoking among American youths is one of the great public health triumphs of the present century. Yet, few people are talking about it. Public health agencies and tobacco control organizations mention it, if at all, in passing. Media coverage is minimal. Should we not be shouting it from the mountaintops?
The Center for the Assessment of Tobacco Regulations (CAsToR)—a collaboration between the University of Michigan, Georgetown University, and the BC Cancer Research Institute—recently received $20 million in funding to continue its research on the impact of tobacco regulations on tobacco use patterns and their downstream health effects.
An online course from the University of Michigan explores the history of smoking in the U.S., the health effects of tobacco and other nicotine products, the tobacco industry's role in the epidemic, the ever-evolving policy landscape, and emerging efforts around the world related to tobacco harm reduction as a complement to traditional tobacco control measures.
Should electronic cigarettes, or vapes, be accepted more widely as an effective and respected tool for treating adult smokers' nicotine addiction? Kenneth Warner, dean emeritus and the Avedis Donabedian Distinguished University Professor Emeritus at the University of Michigan's School of Public Health, says there is enough evidence to support e-cigarettes' use as a first-line aid for smoking cessation in adults.